Profile data is unavailable for this security.
About the company
Cryofocus Medtech Shanghai Co Ltd is a China-based medical device company, focusing on the research, development and commercialization of cryotherapy devices. The Company has built a comprehensive product portfolio comprising two core products, approximately 15 other product candidates in various development stages as well as approximately six additional commercialized medical consumables. The two core products comprise the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Company's products mainly target two therapeutic areas: natural orifice transluminal endoscopic surgery, to treat urinary, respiratory, and digestive diseases (such as bladder cancer, COPD, asthma, airway stenosis, gastric cancer, esophageal cancer and others), and vascular interventional therapy to treat cardiovascular diseases (such as atrial fibrillation, hypertension and others).
- Revenue in HKD (TTM)45.33m
- Net income in HKD-116.03m
- Incorporated2013
- Employees370.00
- LocationCryofocus Medtech Shanghai Co LtdLane 3399Kangxin Highway, Pudong New AreaSHANGHAI 201318ChinaCHN
- Phone+86 2 120977850
- Websitehttps://www.cryofocus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hbm Holdings Ltd | 561.26m | 165.56m | 920.28m | 158.00 | 5.33 | 0.9231 | 4.70 | 1.64 | 0.225 | 0.225 | 0.7613 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,170,948.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
| Jbm (Healthcare) Ltd | 648.42m | 130.46m | 961.74m | 279.00 | 7.91 | 1.00 | 5.23 | 1.48 | 0.1479 | 0.1479 | 0.7338 | 1.17 | 0.4645 | 4.25 | 5.98 | 2,324,068.00 | 9.83 | 4.38 | 12.04 | 5.52 | 52.14 | 46.47 | 21.16 | 12.69 | 1.25 | 89.68 | 0.1155 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.28bn | 1.72k | 5.85 | 0.5343 | 3.64 | 0.8722 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| SinoMab Bioscience Ltd | 2.21m | -218.01m | 1.36bn | 214.00 | -- | 4.51 | -- | 616.82 | -0.2093 | -0.2093 | 0.0021 | 0.277 | 0.0023 | -- | -- | 10,290.54 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Ascletis Pharma Inc | 11.02m | -282.26m | 1.38bn | 219.00 | -- | 0.5998 | -- | 125.63 | -0.2719 | -0.2719 | 0.0106 | 2.35 | 0.0041 | 1.34 | 3.58 | 50,313.48 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.53bn | 1.46k | 5.98 | 0.7575 | 4.80 | 0.9428 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Cryofocus Medtech Shanghai Co Ltd | 45.33m | -116.03m | 1.68bn | 370.00 | -- | 13.03 | -- | 36.98 | -0.4853 | -0.4853 | 0.1896 | 0.5381 | 0.1881 | 0.418 | 4,369.58 | 115,641.70 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.18bn | 614.93m | 1.86bn | 1.18k | 3.03 | 0.5213 | 2.68 | 1.58 | 0.4093 | 0.4093 | 0.7842 | 2.38 | 0.2838 | 2.05 | 6.17 | 1,030,577.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| VIVA Biotech Holdings | 2.18bn | -347.27k | 2.00bn | 2.04k | -- | 0.4814 | 7.85 | 0.9167 | -0.0055 | -0.0055 | 1.06 | 1.93 | 0.2603 | 5.26 | 5.18 | 1,049,038.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
| Golden Throat Holdings Group Co Ltd | 1.10bn | 286.35m | 2.33bn | 860.00 | 8.13 | 1.66 | 7.08 | 2.12 | 0.3873 | 0.3873 | 1.49 | 1.89 | 0.4994 | 3.23 | 4.07 | 1,264,510.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 12 Jul 2023 | 4.92m | 3.43% |
